Molbio Diagnostics shares listed at ₹980, a 21.44% premium to its ₹807 IPO price. Explore its valuation, Truenat growth, key price levels, risks and investor outlook.

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's 2024 fourth quarter and year end results, "2024 was an ...

Second Quarter 2026 Financial Highlights (Compared to the Second Quarter of 2025): Revenue of $8.1 million, an increase of 13.3% compared to $7.1 million, an over 8-year record. Gross Profit of $4.9 ...

This valuable study provides key insights into the role of the G protein-coupled receptor GPR34 in an Alzheimer's disease (AD) model. Notably, its findings differ, at least in part, from those of ...

Asia’s emerging economies and the Middle East & Africa offer strong opportunities amid urbanization and industrialization. The report analyzes market trends, applications, regions and leading ...

Lennox has a very good financial position. Its long-term debt/equity ratio is 1, while the interest coverage ratio is over 22 ...

Xylem stock is a 'Buy' as AI data centers & digital water management drive EPS growth. Here's what investors need to know.

Riparian environments in Colorado would not function properly without the humble river willow amongst its ranks.   These small, spindly, bush-like willows are a far cry in appearance from ...

Topical oil serum combining undecylenic acid, lavender oil, tea tree oil, lemongrass oil, aloe vera, organic flaxseed ...

Against a backdrop of public sentiment and statements pushing rapid adoption of peptides, FDA's PCAC recommends allowing use of six peptides ...

Disposition executed under pre-established Rule 10b5-1 trading plan; Kent retains $4.71 million in direct holdings.